Pheon Therapeutics specializes in developing Antibody-Drug Conjugates (ADCs) to target and treat difficult-to-manage cancers. Their ADCs enhance the precision of cancer therapy by delivering cytotoxic agents directly to tumor cells, minimizing damage to healthy tissue.
Funding
$191.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Many cancers are difficult to treat due to their resistance to conventional therapies and the challenge of selectively targeting tumor cells without harming healthy tissue. Traditional chemotherapy and radiation treatments often result in systemic toxicity and limited efficacy, particularly in hard-to-reach or aggressive tumors.
Solution
Pheon Therapeutics develops next-generation Antibody-Drug Conjugates (ADCs) designed to improve the precision and efficacy of cancer treatment. Their ADCs selectively deliver cytotoxic agents directly to tumor cells, minimizing off-target effects and reducing damage to healthy tissues. By targeting specific antigens expressed on cancer cells, Pheon's ADCs aim to enhance therapeutic outcomes while improving the patient's quality of life. This targeted approach allows for a higher concentration of the drug to reach the tumor site, potentially overcoming resistance mechanisms and improving treatment response.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers, oncologists seeking more effective and targeted therapies, and pharmaceutical companies looking to expand their oncology pipeline.
Features
- Utilizes proprietary linker technology to ensure stable drug delivery and minimize premature release in circulation
- Employs a diverse portfolio of antibodies targeting a wide range of cancer-specific antigens
- Develops ADCs with optimized drug-to-antibody ratios (DAR) for enhanced potency and reduced toxicity
- Focuses on hard-to-treat cancers with limited therapeutic options